TY - JOUR
T1 - Current perspectives in the recognition and management of psoriatic arthritis
T2 - Implications for integrated patient care
AU - Ruderman, Eric M.
PY - 2002/8/26
Y1 - 2002/8/26
N2 - Psoriatic arthritis (Ps), a chronic and debilitating spondyloarthropathy, is believed to affect as many as 30% of those with psoriasis. The use of tumor necrosis factor (TNF) inhibitors shows promise in the treatment of PsA and psoriasis. Etanercept, the first TNF inhibitor to be approved for use in PsA, inhibits the proinflammatory cytokine TNF in both conditions, making it possible for the clinician to prescribe a single agent to manage both the joint manifestations of PsA and the cutaneous manifestations of psoriasis. Etanercept has been shown to be well tolerated, even for long-term use, and is potentially superior to disease-modifying antirheumatic drugs.
AB - Psoriatic arthritis (Ps), a chronic and debilitating spondyloarthropathy, is believed to affect as many as 30% of those with psoriasis. The use of tumor necrosis factor (TNF) inhibitors shows promise in the treatment of PsA and psoriasis. Etanercept, the first TNF inhibitor to be approved for use in PsA, inhibits the proinflammatory cytokine TNF in both conditions, making it possible for the clinician to prescribe a single agent to manage both the joint manifestations of PsA and the cutaneous manifestations of psoriasis. Etanercept has been shown to be well tolerated, even for long-term use, and is potentially superior to disease-modifying antirheumatic drugs.
UR - http://www.scopus.com/inward/record.url?scp=0036345504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036345504&partnerID=8YFLogxK
M3 - Review article
C2 - 11990862
AN - SCOPUS:0036345504
VL - 8
JO - American Journal of Managed Care
JF - American Journal of Managed Care
SN - 1088-0224
IS - 6 SUPPL.
ER -